Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash from Investing Activities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Cash from Investing Activities for 11 consecutive years, with -$38.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 59.05% to -$38.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$276.2 million through Dec 2025, up 49.64% year-over-year, with the annual reading at -$276.2 million for FY2025, 49.64% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$38.3 million at BeOne Medicines, up from -$49.3 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $658.7 million in Q2 2022, with the low at -$209.8 million in Q1 2024.
  • Average Cash from Investing Activities over 5 years is $41.1 million, with a median of -$29.8 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities skyrocketed 1512.96% in 2022, then plummeted 263.76% in 2024.
  • Over 5 years, Cash from Investing Activities stood at -$21.2 million in 2021, then skyrocketed by 281.68% to $38.5 million in 2022, then crashed by 262.4% to -$62.6 million in 2023, then crashed by 49.57% to -$93.6 million in 2024, then soared by 59.05% to -$38.3 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$38.3 million, -$49.3 million, and -$66.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.